Johnson & Johnson has entered a definitive agreement to acquire Alios BioPharma, Inc., a clinical stage biopharma company focused on therapies for viral diseases, for approximately $1.75 billion in cash. Alios’ lead candidate AL-8176 is an orally administered antiviral therapy currently in Phase II development for the treatment of infants with respiratory syncytial virus (RSV).   “We are excited that this acquisition will enable us to explore treatment options for a number of vir...